Amgen’s $3.7 billion acquisition of ChemoCentryx adds new element to autoimmune strategy – MedCity News
Amgen commits nearly $4 billion to acquire ChemoCentryxthe latest in a series of mergers and acquisitions for the pharmaceutical giant and one that is helping the company expand its approach…